Amicus Therapeutics (FOLD) Stock on Dec. 22, 2025: BioMarin’s $14.50 Buyout, Latest News, Analyst Forecasts, and What’s Next
BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics for $14.50 per share in cash, valuing Amicus at about $4.8 billion. Amicus shares traded at $14.18 on Dec. 22, reflecting market focus on deal completion. TD Cowen downgraded Amicus to Hold, setting a $14.50 target. The deal is expected to close in Q2 2026, pending approvals.